Bimatoprost SR for Glaucoma Therapy Implanted at the Slit-Lamp in a Real-World Setting

Abstract

Purpose

To characterize clinical outcomes following a single administration of bimatoprost SR in eyes with glaucoma in a real-world setting implanted at the slit-lamp.

Setting

Tertiary care Glaucoma practice, Glaucoma Associates of Texas, Dallas, Texas.

Design

Retrospective interventional case series.

Methods

Data were analyzed from consecutive patients receiving a single bimatoprost SR implant from the time of its approval to the time of data collection. All eyes were implanted at the slit-lamp. Eyes with less than 1 month of follow-up were excluded. The primary outcome was median time to next intraocular pressure (IOP)-lowering intervention. Mean IOP and medication use, and changes from baseline, were also assessed through 12 months of follow-up.

Results

Overall 129 eyes of 81 patients were analyzed. Following bimatoprost SR administration (replacing a topical prostaglandin analogue [PGA] in most eyes), the median survival time without any further IOP-lowering interventions was between 6–9 months. Mean IOP remained unchanged from baseline at month 1 (consistent with switch from topical to intracameral PGA therapy) and began to rise at month 3. At month 12, 40.5% of eyes (52 eyes) remained intervention-free, mean medication reduction was 0.5 medications per eye, and 27.8% of eyes (36 eyes) were medication-free. Adverse events were uncommon and most were transient and resolved with or without intervention.

Conclusion

This real-world analysis of bimatoprost SR use for glaucoma therapy complements Phase 3 study findings and demonstrates that the implant can safely provide medication reduction through 6 months in most eyes and through 12 months in almost 40% of eyes.

Keywords:

• glaucoma
• bimatoprost SR
• durysta
• sustained release

Disclosure

DSG is a consultant for Allergan and reports grants/personal fees for Medical Advisory Board from Belkin Vision, CATS tonometer, Reichert, Sanoculis, Versant Health and iStar Medical; grants/personal fees from New World Medical and Regeneron; personal fees and minority equity ownership from Nova Eye Medical and Olleyes, outside the submitted work. The authors report no other conflicts of interest in this work.

Additional information

Funding

This study was supported by an Investigator Initiated grant from AbbVie.